Chiropractors in Van Alstyne, TX Accepting Medicare

5 Chiropractors found. Showing 1 - 5

Braddock Chiropractic And Family Wellness Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 119 N. Main St., Van Alstyne, TX 75495 Phone: 903-482-1234    Fax: 903-482-1232

Braddock Chiropractic & Family Wellness Chiropractor Medicare: Medicare Enrolled Practice Location: 119 N Main St, Van Alstyne, TX 75495 Phone: 903-482-1232

Justin Fennell Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 170 N Main St, Van Alstyne, TX 75495 Phone: 972-400-0024

Dr. Alex Castro, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 170 N Main St, Van Alstyne, TX 75495 Phone: 903-482-1234

Dr. Caleb Clifford Braddock, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 119 N Main St, Van Alstyne, TX 75495 Phone: 903-482-1234    Fax: 903-482-1232

News Archive

SNM's Nanomedicine and Molecular Imaging Summit examines the use of nanoparticles

SNM's Nanomedicine and Molecular Imaging Summit wrapped up today in Albuquerque, N.M., with in-depth discussion-and a high sense of energy looking ahead.

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD).

Lupin gets tentative approval from FDA for Armodafinil Tablets, Doxycycline Capsules

elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration.

Viewpoints: Ebola takes us to 'uncharted waters'; the failure of workplace 'wellness' programs

There have been more than 4,300 cases and 2,300 deaths over the past six months. Last week, the World Health Organization warned that, by early October, there may be thousands of new cases per week in Liberia, Sierra Leone, Guinea and Nigeria. What is not getting said publicly, despite briefings and discussions in the inner circles of the world's public health agencies, is that we are in totally uncharted waters and that Mother Nature is the only force in charge of the crisis at this time (Michael T. Osterholm, 9/11).

Anadys Pharmaceuticals reports SVR12 data for ANA598

Anadys Pharmaceuticals, Inc. today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.

Read more Medical News

› Verified 5 days ago